This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Turkish Acquired Haemophilia Registry (EHEM)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Turkish Society of Hematology.
Recruitment status was:  Not yet recruiting
Information provided by:
Turkish Society of Hematology Identifier:
First received: July 26, 2011
Last updated: NA
Last verified: June 2011
History: No changes posted
Turkish Acquired Haemophilia Registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in Turkey.This is a multicentre, retrospective and prospective registry of subjects diagnosed and/or treated for acquired haemophilia. Patients will be registered and the response to different therapies, details of each bleeding episode and the outcome of haemostatic and immunosuppressive therapy (IST) will be recorded. Any male or female subject diagnosed with inhibitors to FVIII or other factors and treated for acquired haemophilia can be entered on the registry. Patients will be treated according to local practice. No additional tests or procedures are required by the registry. The retrospective period will not be time-limited and data will be collected from those recorded in the hospital notes. The prospective period will begin in September 1.2011, and will last for two years.

Condition Intervention
Acquired Haemophilia Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin

Study Type: Observational
Official Title: Observational Acquired Haemophilia Registry

Resource links provided by NLM:

Further study details as provided by Turkish Society of Hematology:

Biospecimen Retention:   Samples Without DNA
Blood sample for coagulation factor determination

Estimated Enrollment: 250
Study Start Date: September 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Acquired haemophilia patients Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
According to local clinical standards


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acquired haemophilia diagnosed and/or treated in haematology clinics

Inclusion Criteria:

  • Acquired haemophilia diagnosis, written consent

Exclusion Criteria:

  • Being unable to give written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01403740

Contact: Dilek Solakoglu, MD 902123253232
Contact: Volkan Aydin, MD 902123253232

Trakya University Haematology Clinic Not yet recruiting
Edirne, Turkey, 22030
Contact: Muzaffer A Demir, Prof    902842351041   
Contact: Dilek Solakoglu, MD    902123253232   
Principal Investigator: Muzaffer A Demir, Prof         
Sponsors and Collaborators
Turkish Society of Hematology
Principal Investigator: Muzaffer A Demir, Prof THD
  More Information

Responsible Party: Turkish Society of Hematology Identifier: NCT01403740     History of Changes
Other Study ID Numbers: 2011/HEM/001
Study First Received: July 26, 2011
Last Updated: July 26, 2011

Keywords provided by Turkish Society of Hematology:
acquired haemophilia
factor VIII

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Calcineurin Inhibitors
Antimetabolites, Antineoplastic processed this record on September 21, 2017